Abstract
MoST-LLy (Molecular Screening and Therapeutics in Leukaemia and Lymphoma) has a unique study design with molecular screening using Illumina’s TruSight™ Oncology 500 Next Generation Sequencing (NGS) assay, and linking patients with advanced haematological malignancy with no standard of care treatment, to access targeted clinical trials and treatments they would otherwise not have access to. The overarching MoST framework protocol governs molecular screening with each substudy reviewed and approved as an addenda to the program. We have developed two novel haematology specific treatment substudies with pharma that will soon open to recruitment, including:•MoST 15: durvalumab + acalabrutinib for high-grade B cell lymphoma.•MoST 16: PARP inhibitor for relapsed/refractory myeloid haematological malignancy. MoST-LLy is the first molecular screening of its kind in blood cancers in Australia, and is being piloted across two sites initially with funding provided by the Leukemia Foundation of Australia and Tour de Cure to screen 240 patients, with plans to roll out nationally.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
